Avihingsanon, A., Lu, H., Leong, C. L., Hung, C. C., Koenig, E., Kiertiburanakul, S., ... & Li, T. (2023). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV, 10(10), e640-e652. - https://pubmed.ncbi.nlm.nih.gov/37494942/
Deeks, E. D. (2014). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection. Drugs, 74(17), 2079-2095 - https://pubmed.ncbi.nlm.nih.gov/25352394/
Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A. (2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV, 7(10), e666-e676 - https://pubmed.ncbi.nlm.nih.gov/33010240/
Frampton, J. E., & Croom, K. F. (2006). Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs, 66(11), 1501-1512 - https://pubmed.ncbi.nlm.nih.gov/16906786/
Dando, T. M., & Wagstaff, A. J. (2004). Emtricitabine/tenofovir disoproxil fumarate. Drugs, 64(18), 2075-2082 - https://pubmed.ncbi.nlm.nih.gov/15341498/